Basic Information
| LncRNA/CircRNA Name | CASC9 |
| Synonyms | CASC9, ESCCAL-1, ESSCAL1, LINC00981 |
| Region | GRCh38_8:75223404-75324741 |
| Ensemble | ENSG00000249395 |
| Refseq | NR_103848 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Cell transfection, Western blot, Cell proliferation assay etc. |
| Sample | gastric cancer tissues, cell lines (BGC823 and SGC7901) |
| Expression Pattern | up-regulated |
| Function Description | CASC9 was overexpressed in gastric cancer (GC) compared to normal gastric tissue. Moreover, the expression of CASC9 was even higher in BGC823/DR and SGC7901/DR cells that are resistant to paclitaxel or adriamycin. CASC9 knockdown inhibited proliferation and promoted cell apoptosis In BGC823/DR and SGC7901/DR cells. The invasion potential was also significantly inhibited measured by Transwell assay. In addition, CASC9 knockdown in BGC823/DR and SGC7901/DR cells restored chemosensitivity to paclitaxel and adriamycin. |
| Pubmed ID | 28146436 |
| Year | 2017 |
| Title | Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. |
External Links
| Links for CASC9 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |